Core Viewpoint - RIMBACO (1953.HK) experienced a significant intraday increase of 107.69%, reaching a new high of 0.27 HKD since December 2022, despite low trading volume of less than 4 million HKD [1] Summary by Relevant Sections - **Stock Performance** - The stock price of RIMBACO surged by 107.69% to 0.27 HKD, marking the highest level since December 2022 [1] - Trading volume remained low, with less than 4 million HKD transacted [1] - **Dividend Announcement** - The company declared a special dividend of 3.7 HKD cents per share [1] - This special dividend is scheduled to be paid on September 15, 2023, to shareholders listed as of the close of business on September 4, 2023 [1]

Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) has applied for the listing and trading of 112.7 million H-shares on the Hong Kong Stock Exchange, based on the assumption that all shareholders will convert their shares according to the exchange ratio and merger agreement [1][2] Group 1 - The company plans to privatize Dongyang Sunshine Changjiang Pharmaceutical by issuing H-shares as consideration to acquire the H-shares held by shareholders, with a conversion ratio of 0.263614 new H-shares for each H-share of Dongyang Sunshine Changjiang Pharmaceutical [2] - A special dividend of HKD 1.50 per share will be paid to shareholders of Dongyang Sunshine Changjiang Pharmaceutical, who collectively hold approximately 427.6 million shares, upon the completion of the privatization [2] - Upon completion of the privatization, Dongyang Sunshine Changjiang Pharmaceutical's listing status on the exchange will be revoked, and the company will assume all assets, liabilities, and rights of Dongyang Sunshine Changjiang Pharmaceutical [2] Group 2 - The H-shares will be eligible securities for Hong Kong clearing once approved for listing and trading, allowing for deposit, settlement, and transfer in the central clearing system [3]